Siskinds | The Law Firm
Pharmaceutical and Medical Devices > Resolved Actions > Zyprexa
    Zyprexa

    Frequently Asked Questions about the Zyprexa Settlement [PDF Document]

    UPDATE (October 25, 2011): The claims deadline has now passed and all claims have either been approved or rejected. The courts are currently in the process of determining the remaining appeals. Once all appeals have been determined, the final amount of the settlement can be calculated which triggers 30 days for the defendants to pay the balance of the settlement funds to the claims administrator. Once the claims administrator receives the settlement funds, they will then be able to process the settlement payments.


    UPDATE (June 30, 2010): The Zyprexa settlement has now been approved by the courts in each jurisdiction. The claims deadline is October 28, 2010. It is important that you start preparing your claim well in advance of that deadline as there are records that need to accompany your claim which may still need to be acquired. For further information, please refer to the attached notice, claim form, and press release and/or do not hesitate to contact us with any questions.


    UPDATE (June 11, 2010): We are pleased to announce that the settlement has been approved by the Ontario Superior Court of Justice.


    UPDATE (May 21, 2010): We are pleased to announce that a settlement has been reached in this action:

    The next step is to have the settlement approved by the courts. Settlement approval hearings have been scheduled for Ontario on June 8 , 2010, Quebec on June 14, 2010, and British Columbia on June 15, 2010.

    Once the settlement has been approved by each of the courts, a further notice will be published which will explain the steps for making a claim.


    In December 2004, Siskinds filed a class proceeding against Eli Lilly Canada Inc., and Eli Lilly and Company with respect to Zyprexa. Zyprexa ("olanzapine") is a drug approved for use in Canada to treat schizophrenia and bi-polar disorder. Use of Zyprexa has been linked to increased risk of developing diabetes and other health related problems.

    On February 6, 2007, the Honourable Justice Cullity of the Ontario Superior Court of Justice certified this case as a class proceeding. A copy of Justice Culllity's reasons for decision are posted below.

    Siskinds is working with a national class counsel team to ensure the most effective representation possible for the class.

    In Ontario, the action is being case managed by The Honourable Mr. Justice Cullity who has established a schedule for the orderly exchange of materials.

    For further information concerning this action, please contact us at 519-672-2251 ext. 1101 or e-mail by clicking on the Contact Us link below.



    Download Adobe reader

    The documents available on this page require the latest version of Adobe Acrobat Reader for viewing.Les documents disponibles sur cette page nécessitent la dernière version d’Adobe Acrobat Reader pour les visionner.
    Cliquez ici pour télécharger.Click Here to download.